AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Licensing agreement focuses on cancer vaccines.(Brief Article)
2002 AUG 14 - (NewsRx.com & NewsRx.net) -- Epimmune, Inc., (EPMN), a biotechnology company focused on the development of pharmaceutical products using multiple, specific epitopes to activate the body's immune system, announced that it had entered into an evaluation and license option agreement with Aventis Pasteur Limited.
Under the terms of the agreement, Aventis Pasteur will have, for a limited period of time, the right to exercise its option to license from Epimmune certain epitopes from two cancer associated antigens. Aventis Pasteur will evaluate the epitopes for possible integration into its poxvirus therapeutic cancer vaccine program.
Should Aventis Pasteur exercise its rights under the agreement, it will have an exclusive license to use the epitopes in connection with its proprietary poxvirus delivery system in several cancer fields. Epimmune received an evaluation license fee and is further entitled to receive a license fee if Aventis Pasteur exercises its option, and precommercialization milestones and royalties on product sales if Aventis Pasteur develops products utilizing the Epimmune technology.
"This agreement provides an opportunity for Aventis Pasteur to extend our leadership role in the area of pox-based vaccines by providing access to the epitope expertise ...
- Aventis Pasteur Acquires Exclusive Rights to Develop Novel Cancer Targets...
- Press release article from: PR Newswire January 13, 2003 700+ words
...safe and effective cancer vaccines. Aventis Pasteur will apply its recognized...important disease. Aventis Pasteur is the company with...resources to make cancer vaccines a reality." About Aventis Pasteur: Aventis Pasteur...
- AVENTIS PICKS FIVE EOS TARGETS; VACCINE DEAL ENDS WITH 'BANG'.(Aventis Pasteur,...
- Magazine article from: BIOWORLD Today Osborne, Randall January 14, 2003 700+ words
Byline: Randall Osborne , National Editor Two years after starting their deal for cancer vaccines, Aventis Pasteur has exercised its option to develop up to five targets discovered by Eos Biotechnology Inc., hitting the first major milestone...
- A New Weapon in the Battle Against Cancer; Aventis Pasteur opts for Ontario as...
- Press release article from: PR Newswire January 13, 2004 700+ words
...deadliest diseases. Aventis Pasteur, a world leader...chemotherapy. Two cancer vaccines, for colorectal...in breast cancer. Aventis Pasteur's goal is to generate...series of therapeutic cancer vaccines so that one will...
- Eos Biotechnology and Aventis Pasteur Announce Major Genomics-Based Cancer...
- Press release article from: PR Newswire June 6, 2000 700+ words
...products. Aventis Pasteur, the world...development of cancer vaccines in two specific...agreement, Aventis Pasteur will obtain...therapy." "Cancer vaccines will serve...Development, Aventis Pasteur. "Our research...
- ZYCOS and Aventis Pasteur extend drug discovery collaboration After First...
- Press release article from: Business Wire June 25, 2001 700+ words
...preventative in nature, Aventis Pasteur's vaccine approach...novel drug targets. Aventis Pasteur researchers are using...collaboration to design novel cancer vaccines that will "turn...collaboration with Aventis Pasteur is a direct result...
- Therion Biologics.(collaborates with Aventis Pasteur for cancer vaccine)(Brief...
- Magazine article from: Chemistry and Industry November 20, 2000 700+ words
Vaccine developers Therion Biologics, Cambridge, Massachusetts, US, and Aventis Pasteur, Toronto, Canada, are to expand their existing collaboration to study tumour-associated antigens for cancer vaccines.
- Aventis Pasteur Announces Closing of Virogenetics Facility.
- Press release article from: PR Newswire June 22, 2000 700+ words
...Board of Directors. Aventis Pasteur first became affiliated...clinical trials. Aventis Pasteur intends to continue...vaccines and therapeutic cancer vaccines that are being conducted...activities at the Aventis Pasteur facility in Toronto...
- Cancer Vaccines on the Web; New Site Highlights Progress, Potential.
- Press release article from: PR Newswire June 21, 2002 700+ words
...potential of therapeutic cancer vaccines. Aventis Pasteur is leading an international...find out more about the Aventis Pasteur cancer vaccine program...Contact: Nancy Simpson of Aventis Pasteur Limited, Toronto, +1...
Source: HighBeam Research, Licensing agreement focuses on cancer vaccines.(Brief Article)